Galectin Therapeutics Inc
PHPN
Company Profile
Business description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Contact
4960 Peachtree Industrial Boulevard
Suite 240
NorcrossGA30071
USAT: +1 678 620-3186
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
How I lost all my savings through a poor investment decision
With first timers at risk of poor investment decisions and an interest in speculative stocks, I explore my biggest investing mistake.
stocks
Chart of the Week: Morningstar’s forecast for CSL’s future
We see gross margin expansion on efficiencies and limited tariff impact
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,063.40 | 33.90 | 0.38% |
| CAC 40 | 7,767.88 | 59.57 | -0.76% |
| DAX 40 | 23,428.08 | 238.73 | -1.01% |
| Dow JONES (US) | 46,121.28 | 171.50 | -0.37% |
| FTSE 100 | 9,216.03 | 34.40 | -0.37% |
| HKSE | 26,484.68 | 33.97 | -0.13% |
| NASDAQ | 22,497.86 | 75.62 | -0.33% |
| Nikkei 225 | 45,754.93 | 124.62 | 0.27% |
| NZX 50 Index | 13,153.79 | 27.52 | -0.21% |
| S&P 500 | 6,637.97 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,773.00 | 35.10 | 0.40% |
| SSE Composite Index | 3,853.30 | 0.34 | -0.01% |